细胞因子诱导杀伤细胞联合mFOLFOX6方案用于晚期结直肠癌的效果分析  

Analysis the effect of cytokine‑induced killer cells combined with mFOLFOX6 regimen in chemotherapy for advanced colorectal cancer

作　　者：王俊杰 吕九娣 彭昕 Wang Junjie;Lyu Jiudi;Peng Xin(Department of Medical Oncology,the Fourth Clinical College,Xinxiang Medical College,Xinxiang Central Hospital,Xinxiang 453000,China;Department of Surgical Oncology,the Fourth Clinical College of Xinxiang Medical College,Xinxiang Central Hospital,Henan Province,Xinxiang 453000,China)

机构地区：[1]河南省新乡市中心医院、新乡医学院第四临床学院肿瘤内科,新乡453000 [2]河南省新乡市中心医院、新乡医学院第四临床学院、肿瘤外科,新乡453000

出　　处：《中华医学杂志》2023年第26期2000-2005,共6页National Medical Journal of China

摘　　要：目的探讨细胞因子诱导杀伤细胞(CIK)联合mFOLFOX6方案(氟尿嘧啶+奥沙利铂+亚叶酸钙)用于晚期结直肠癌的效果。方法回顾性选取2019—2021年河南省新乡市中心医院新乡医学院第四临床学院收治的161例晚期结肠癌患者,根据治疗方法将其分为研究组(mFOLFOX6方案化疗+CIK疗法)80例和对照组81例(mFOLFOX6方案化疗);比较2组患者化疗前后的卡氏评分(KPS评分)、中位生存期、无进展生存期、外周血单个核细胞中Treg占比、CD4+、CD4+/CD8+水平、Foxp3、CD127 mRNA表达水平、生存质量评分及患者的毒副反应发生情况。结果研究组和对照组患者的年龄分别(64.8±7.5)、(66.1±7.0)岁,男性比例分别为62.5%(50例)、50.6%(41例)(均P>0.05)。化疗2个周期、化疗结束后,研究组患者Treg、Foxp3、CD127 mRNA占比均低于对照组患者[化疗2个周期:(4.33±0.86)%比(4.89±1.20)%,0.61±0.22比0.73±0.20,0.58±0.13比0.70±0.15;化疗结束后:(2.66±0.70)%比(3.31±0.84)%,0.43±0.18比0.51±0.16,0.41±0.10比0.50±0.13](均P<0.05);研究组患者KPS评分均高于对照组患者[化疗2个周期:(68.41±5.41)分比(65.38±5.11)分;化疗结束后:(72.08±5.94)分比(67.95±5.51)分](均P<0.05)。研究组患者的中位生存期为(16.8±2.2)个月,高于对照组的(11.2±1.8)个月,无进展生存期也高于对照组[(9.5±1.1)比(6.4±1.2)个月],死亡率低于对照组[11.3%(9例)比31.3%(25例)](均P<0.001)。化疗结束后,研究组的躯体功能、情绪功能、角色功能评分高于对照组,研究组疼痛、疲倦、失眠评分低于对照组,差异均具有统计学意义(均P<0.05)。结论CIK联合mFOLFOX6方案用于晚期结直肠癌能改善和调节患者的免疫功能,延长患者的生存时间,改善患者的生存质量。Objective To investigate the effect of cytokine‑induced killer cells(CIK)combined with mFOLFOX6 regimen(fluorouracil+oxaliplatin+calcium folinate)on advanced colorectal cancer.Methods 161 patients with advanced colon cancer admitted to the Fourth Clinical College of Xinxiang Medical College,Xinxiang Central Hospital of Henan Province from 2019 to 2021 were selected and divided into the study group(mFOLFOX6 regimen chemotherapy+CIK therapy)with 80 cases and the control group(mFOLFOX6 regimen chemotherapy)with 81 cases.The KPS score,median survival time,progression‑free survival time,the proportion of Treg in peripheral blood mononuclear cells,the levels of CD4+,CD4+/CD8+,the expression levels of Foxp3 and CD127 mRNA,the quality‑of‑life score and the occurrence of toxic and side effects were compared between the two groups before and after chemotherapy.Results The ages of patients in the study group and the control group were(64.8±7.5)and(66.1±7.0)years old,respectively,and the proportions of males were 62.5%(50 cases)and 50.6%(41 cases),respectively(both P values>0.05).After 2 cycles of chemotherapy and at the end of chemotherapy,the proportions of Treg,Foxp3 and CD127 mRNA in the study group were lower than those in the control group[2 cycles of chemotherapy:(4.33±0.86)%vs(4.89±1.20)%,(0.61±0.22)vs(0.73±0.20),(0.58±0.13)vs(0.70±0.15);after chemotherapy:(2.66±0.70)%vs(3.31±0.84)%,(0.43±0.18)vs(0.51±0.16),(0.41±0.10)vs(0.50±0.13)](all P values<0.05).The KPS scores of the study group were higher than those of the control group[2 cycles of chemotherapy:(68.41±5.41)points vs(65.38±5.11)points;after chemotherapy:(72.08±5.94)points vs(67.95±5.51)points](all P values<0.05).The median survival time of the study group was(16.8±2.2)months,which was higher than that of the control group[(11.2±1.8)months].The progression‑free survival time of the study group was also higher than that of the control group[(9.5±1.1)months vs(6.4±1.2)months],and the mortality rate was lower than that of the contro

关 键 词：结直肠肿瘤 细胞因子诱导杀伤细胞 氟尿嘧啶 奥沙利铂 亚叶酸钙 晚期 结直肠癌 

分 类 号：R735.34[医药卫生—肿瘤]